XCancer

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Description:

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Sponsor:

AstraZeneca

Contacts:

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Government Study Link:

NCT06879041 - Click here to see study on

ClinicalTrials.gov

[225Ac]-AZD2284

Isotope(s):
Target(s):
  • STEAP2
Ligand Class: Antibodies